Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2025

Core Insights - Resmed Inc. reported strong financial performance for the third quarter of fiscal year 2025, with significant revenue growth, margin expansion, and double-digit earnings per share (EPS) growth driven by robust customer demand for its products and software solutions [2][3]. Financial Performance - Revenue for the quarter ended March 31, 2025, was $1,291.7 million, an increase of 8% year-over-year, and 9% on a constant currency basis [4][6]. - Gross margin improved by 140 basis points to 59.3%, while non-GAAP gross margin also increased by 140 basis points to 59.9% [4][6]. - Income from operations rose by 14% to $426.3 million, with non-GAAP income from operations increasing by 13% to $444.6 million [4][6]. - Net income for the quarter was $365 million, representing a 21% increase compared to the previous year, and diluted EPS was $2.48, up 22% [4][6]. Operational Highlights - The company emphasized its commitment to addressing the needs of over 2.3 billion people globally with sleep health and breathing health issues [3]. - Resmed's Residential Care Software revenue grew by 10% on a constant currency basis, reflecting continued organic growth in this segment [9]. - The company reported operating cash flow of $579 million for the quarter, with $107 million received in tax refunds from the IRS [5][9]. Product and Market Performance - Revenue in the U.S., Canada, and Latin America grew by 9%, while revenue in Europe, Asia, and other markets increased by 8% on a constant currency basis [9]. - The demand for sleep devices and masks, as well as growth in the Residential Care Software business, contributed to the overall revenue increase [9][24]. Dividend Declaration - The board of directors declared a quarterly cash dividend of $0.53 per share, with a record date of May 8, 2025, and payable on June 12, 2025 [10].